For the once-weekly subcutaneous formulation, the SUSTAIN program (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) included 13 separate randomized clinical phase 3a and 3b trials ( Table 1 Overview of Phase 3 studies of oral semaglutide (PIONEER) and subcutaneous semaglutide (SUSTAIN) ( *Phase 3b trials all others are phase 3a trials CKD, chronic kidney disease
Non-pharmacological strategies (first-line): For nausea: Dietary modifications : Eat smaller, more frequent meals
The return on time invested is extraordinary
[4] [19] Estas pueden incluir: Enrojecimiento (eritema) Picazn o prurito Hinchazn o induracin Sensibilidad o dolor localizado Estas reacciones locales generalmente son leves, autolimitadas y se resuelven en pocos das sin intervencin especfica
While some would consider that figure to be jaw-dropping, it could have been a lot higher had it not been for the ongoing drug shortage, which has had a significant impact on the GLP-1 market
Switching to a smaller gauge needle to inject means less pain and not using the needle more than once
